Just published is a new OHE Consulting Report entitled: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? The purpose of the new OHE report is to explore a review exercise undertaken by NICE and the University of York and to assess whether or not the resulting conclusions are appropriate.
Professor Andrea Manca from the University of York will lead an OHE Lunchtime Seminar on 13th February 2017 on the topic of economic evaluation for decision-making and the value of access to individual patient data.
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016. The level of patient access associated with these decisions has also been assessed.
OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to the Mexican decision making system as a case study.
Hernandez-Villafuerte, K., Garau, M., Towse, A., Garrison, L. and Grewal, S.
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion.
This report presents a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and micro-level factors (looking at intervention-specific effects) to determine the overall value of medicines.
This Research Paper explores decisions by the National Institute for Health and Care Excellence (NICE) that new technologies are to be recommended in line with clinical practice (RiLCP). The authors qualitatively assess documentation associated with RiLCP decisions to create a framework to describe common themes, and assess the level of patient access associated with each RiLCP decision.
This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to assess the value of obinutuzumab for rituximab-refractory iNHL.